PPARG and type 2 diabetes mellitus: Multiple studies have suggested that pioglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, used as an insulin-sensitizing agent in the treatment of type 2 diabetes mellitus (T2DM), may have anti-atherosclerotic effects [2, 8–10].